VEGFR

Inhibitory Selectivity

Catalog No.	Inhibitor Name	VEGFR1	VEGFR2	VEGFR3	Other
A10001	Sorafenib Tosylate		**		Raf-1,B-Raf,B-Raf (V599E)
A10880	Sunitinib Malate		*		Kit,FLT3,PDGFRβ
A10996	Cabozantinib	***	****	***	c-Met,Kit,Axl
A10080	Ponatinib		****		Abl,PDGFRα,FGFR1
A10103	Axitinib	****	****	****	PDGFRβ,Kit,PDGFRα
A10998	Foretinib	***	****	****	Met,Tie-2,RON
A10963	Vandetanib		**	*
A10137	Nintedanib	**	***	***	LCK,FLT3,FGFR2
A10250	Regorafenib	***	****	*	RET,Raf-1,Kit
A11518	Pazopanib HCl	***	**	*	FGFR,PDGFR,c-Kit
A10185	Cediranib	***	****	****	c-Kit,PDGFRβ,FGFR1
A10703	PD173074		*		FGFR1,c-Src
A11411	Dovitinib	***	***	***	FLT3,c-Kit,FGFR1
A10025	Linifanib	****	****	*	CSF-1R,FLT3,Kit
A10967	Vatalanib 2HCl	*	**	*	PDGFRβ,c-Kit,c-Fms
A10773	RAF265		**		B-Raf
A10101	Tivozanib	**	***	**	EphB2,PDGFRα,PDGFRβ
A10608	Motesanib Diphosphate	****	****	***	Kit,RET,PDGFR
A10340	Lenvatinib	**	****	***	PDGFRβ,FGFR1,PDGFRα
A10953	Orantinib		*		PDGFRβ,FGFR1
A10254	Brivanib	*	**		FGFR1
A10587	MGCD-265	****	****	****	Met,RON,Tie-2
A10043	AEE788	*	*	*	EGFR,HER2/ErbB2,c-Abl
A10352	ENMD-2076		*	**	FLT3,RET,Aurora A
A10679	OSI-930	***	***		CSF-1R,LCK,C-Raf
A10248	CYC116		**		Aurora A,Aurora B,FLT3
A10502	Ki8751		****		c-Kit,PDGFRα,FGFR2
A10903	Telatinib		***	****	c-Kit,PDGFRα
A11518	Pazopanib	***	**	*	FGFR,PDGFR,c-Kit
A10504	KRN 633	*	*	*	PDGFRα,c-Kit,BTK
A13377	SAR131675			**
A10198	Dovitinib Dilactic Acid	***	***	***	FLT3,c-Kit,FGFR1
A11407	Apatinib		****		RET,c-Kit,c-Src
A10154	BMS-794833		**		Met
A10162	Brivanib Alaninate	*	**		FGFR1
A11396	Golvatinib		**		c-Met
A11954	ZM 323881 HCl		****
A11955	ZM 306416	*			Src,Abl
A16342	BFH772		****
A11558	SU5402		**		FGFR1,PDGFRβ
A12437	Semaxanib		*
A11244	LY2874455		***		FGFR2,FGFR1,FGFR4
A13234	SKLB1002		**
A14156	AZD2932		***		PDGFRβ,Flt3,c-Kit
A10893	Taxifolin (Dihydroquercetin)
A11772	CP-547632		***		FGFR
A12693	BAW2881 (NVP-BAW2881)	*	***	*	C-Raf-1,B-RAFV599E,c-Abl
A13465	SKLB610		*		PDGFR, FGFR2
A13819	TG 100801	****	***		FGFR1, Fyn, Src
A13820	TG 100572	****	***		FGFR1, Fyn, Src
A14387	ltiratinib (DCC2701)		***		MET, TIE2, TRK
A15073	E-3810	***	**	***	FGFR-1, FGFR-2
A15287	ZM323881		****
A15792	BMS-817378		***		c-Met

Notes:
1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Catalog No.	Product Name	Application	Product Information
A15073	E-3810	VEGFR/FGFR Inhibitor	E-3810 is a potent and selective dual inhibitor of VEGF and FGF receptors with IC50 values of 7 nM, 25 nM, 10 nM, 17.5 nM and 82.5 nM for VEGFR-1, VEGFR-2, VEGFR-3, FGFR-1 and FGFR-2, respectively.
A15760	SU10944	VEGFR Inhibitor	SU10944 is a small molecule kinase inhibitor of VEGFR that inhibits neovascularization and permeability, and is distributed to the eye upon systemic delivery.
A15287	ZM323881	VEGFR Inhibitor	ZM323881 is a potent and selective inhibitor of human vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) with IC50 value of 2 nM.
A15271	Vandetanib HCl	VEGFR inhibitor	Vandetanib is a potent inhibitor of VEGFR2 with IC50 of 40 nM.
A15261	TG 100801 HCl	VEGFr2 inhibitor	TG 100801 is the prodrug of TG 100572 (HY-10184), TG 100572 is a multi-targeted kinase inhibitor that inhibit select growth factor receptor tyrosine kinases and Src familt kinases with IC50 values of 2/7/2/1/0.5 nM or VEGFR1/VEGFR2/FGFR1/Src/Fyn kianse respectively.
A15260	TG 100572 HCl	VEGFR2/Src kinase inhibitor	TG 100572 is a multi-targeted kinase inhibitor that inhibit select growth factor receptor tyrosine kinases and Src familt kinases with IC50 values of 2/7/2/1/0.5 nM for VEGFR1/VEGFR2/FGFR1/Src/Fyn kianse respectively.
A15250	SU14813 double bond Z	VEGFR Inhibitor	SU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), Kit, and fms-like tyrosine kinase 3 (FLT-3).
A15182	N-Desethyl Sunitinib	VEGFR/PDGFRβ/KIT inhibitor	N-desethyl sunitinib is a major and pharmacologically active metabolite of sunitinib, which is potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor (Ki values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT respectively).
A11772	CP-547632	VEGFR2 inhibitor	CP-547632 is a novel, potent vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor
A11496 SALE	Motesanib (AMG706)	VEGFR Inhibitor	Motesanib (AMG706) is a multikinase inhibitor that selectively targets VEGF receptors, platelet-derived growth factor receptors (PDGFRs), and Kit receptors with IC?? values of 2 nM (VEGFR1), 3 nM (VEGFR2), 6 nM (VEGFR3), 84 nM (PDGFR), and 8 nM (Kit). Product Citations (1) Angela Coxon,etc. Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non–small-cell lung cancer xenograft models. Mol Cancer. 2012; 11: 70.
A11557	SU14813	VEGFR Inhibitor	SU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), KIT, and fms-like tyrosine kinase 3 (FLT-3)
A11558 SALE	SU-5402	VVEGFR/FGFR/EGFR inhibitor‎	SU-5402 is a potent and selective vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor (IC50 values are 0.02, 0.03, 0.51 and > 100 μM at VEGFR2, FGFR1, PDGFRβ and EGFR respectively). Product Citations (1) Yan Zhang, etc. Endogenously produced FGF2 is essential for the survival and proliferation of cultured mouse spermatogonial stem cells. Cell Res. 2012 Apr; 22(4): 773–776.
A11581 SALE	Toceranib (PHA 291639, SU 11654)	c-Kit, PDGFR, VEGFR inhibitor	Toceranib is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ. Product Citations (1) Masaya Igase,et al. Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumor, Can J Vet Res, 2016, Jan; 80(1): 21-31 26733729
A13111 SALE	R1530	Chk2, KDR, FGFR, Aurora A & Cdk2 inhibitor	R1530 is a pyrazolobenzodiazepine small molecule with potential antiangiogenesis and antineoplastic activities. R1530 is also a mitosis-angiogenesis inhibitor (MAI) that inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta? FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2.
A13234	SKLB1002	VEGFR inhibitor	SKLB1002 is a new potent VEGFR2 inhibitor, which could significantly inhibit HUVEC proliferation, migration, invasion, and tube formation.
A12437 SALE	SU 5416 (Semaxinib)	VEGFR Inhibitor	SU 5416 is an inhibitor of vascular endothelial growth factor receptor (VEGFR) that also inhibits other tyrosine kinases KIT, MET, FLT3 and RET.
A11396 SALE	E-7050 (Golvatinib)	-	E7050 (also known as golvatinib is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity.
A11244 SALE	LY 2874455	FGFR/VEGFR2 inhibitor	LY2874455 is a novel and potent FGFR/VEGFR Inhibitor.
A12027 SALE	(-)-Catechin gallate	-	(-)-Catechin gallate is an antioxidant constituent of green tea. At uM concentrations, inhibits VEGF-induced tyrosine phosphorylation. Product Citations (2) MS Islam ,etc. Effect of UV Irradiation on the Nutritional Quality and Cytotoxicity of Apple Juice. Journal of Agricultural and Food Chemistry, 2016, 64(41), 7812-7822. MS Islam ,etc. UV-C irradiation as an alternative disinfection technique: Study of its effect on polyphenols and antioxidant activity of apple juice. Innovative Food Science & Emerging Technologies, 2016, 34, 344-351.
A11955	ZM 306416 hydrochloride	VEGFR Inhibitor	ZM 306416 is a VEGF receptor tyrosine kinase inhibitor that inhibits KDR (IC50 = 100 nM) and Flt (IC50 = 2 uM) tyrosine kinases.
A11954	ZM 323881 hydrochloride	VEGFR Inhibitor	ZM 323881 is a potent and selective inhibitor of the kinase activity of the human vascular endothelial growth factor receptor 2 (VEGFR2/KDR).
A11737 SALE	Buflomedil HCl	VEGFR Antagonist	Buflomedil is a vasoactive agent used to treat peripheral vascular disease.
A11518 SALE	Pazopanib (GW-786034)	VEGFR inhibitor	Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis. Product Citations (3) Koide H,et al. Substrate-dependent effects of molecular-targeted anticancer agents on activity of organic anion transporting polypeptide 1B1, Xenobiotica, 2018, Oct;48(10):1059-1071 29034773 Ellawatty WEA,et al. Organic cation transporter 1 is responsible for hepatocellular uptake of the tyrosine kinase inhibitor pazopanib, Drug Metab Dispos, 2018, Jan;46(1):33-40 29089306 Fujita KI,et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 28479358
A11263	BMS-690514	VEGFR/EGFR Inhibitor	BMS-690514 is a potent and selective inhibitor of epidermal growth factor receptor (EGFR), HER2, and HER4, as well as the VEGF receptor kinases.
A13820	TG 100572	VEGFR2/Src inhibitor	TG 100572 is VEGFR2 and Src kinase inhibitor.
A13819	TG 100801	VEGFR2/Src inhibitor	TG 100801 is a VEGFR2 targeting prodrug currently in a clinical trial. The active form is TG100572.
A11472 SALE	Ki 20227	M-CSFR, CSF1R inhibitor	Ki 20227 is an inhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R). Product Citations (1) Wensheng Wang,et al. Lymphatic endothelial cells produce M-CSF causing massive bone loss in mice, J Bone Miner Res, 2017, May; 32(5): 939-950 28052488
A16237	EG00229	neuropilin-1/VEGF-A inhibitor	EG00229 is the first small molecule inhibitors of the neuropilin-1 and VEGF-A interaction with an IC50 of inhibition of 8 uM(125I-VEGF binding to PAE/NRP1 cells).
A16197	Nintedanib esylate	RTK inhibitor	Nintedanib is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs).
A12693 SALE	NVP-BAW2881	VEGFR inhibitor	NVP-BAW2881 is a potent and selective VEGFR inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor) with activity to inhibit chronic and acute skin inflammation.
A13240	NVP-ACC789	VEGFR-2 inhibitor	NVP-ACC789 is an inhibitor of VEGFR-2 (FLK-1/KDR).
A14387	Altiratinib (DCC2701)	c-Met/VEGFR inhibitor	Altiratinib is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro.
A15792	BMS-817378	MET/VEGFR-2 inhibitor	BMS-817378 is a novel prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833.
A15272	Vandetanib trifluoroacetate	VEGFR/EGFR inhibitor	Vandetanib is a potent inhibitor of VEGFR2 with IC50 of 40 nM.
A15263	Toceranib phosphate	-	Toceranib phosphate is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ.
A15218	Regorafenib monohydrate	Tyrosine kinase inhibitor	Regorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.
A13555	TAK-593	VEGFR/PDGFR inhibitor	TAK-593 is an oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with potential antineoplastic activity.
A13545	JI-101	VEGFR2/PDGFRβ/EphB4 inhibitor	JI-101 is an orally active inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFRβ), and the ephrin B4 receptor B4 (EphB4) with potential antiangiogenic and antineoplastic activities.
A14393	Fruquintinib	VEGFR inhibitor	Fruquintinib is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities.
A14156	AZD 2932	mutil-targeted protein tyrosine kinase inhibitor	AZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively.
A13465	SKLB610	VEGFR inhibitor	SKLB610 is a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
A13377	SAR131675	VEGFR3 Inhibitor	SAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities.
A16342	BFH772	VEGFR2 inhibitor	BFH772 is a potent oral VEGFR2 inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC50 value of 3 nM.
A10504	KRN 633	VEGFR Inhibitor	KRN 633 is a cell-permeable, reversible, ATP-competitive VEGFR kinase inhibitor that inhibits PDGFR-α and c-Kit at higher concentrations only (IC50 = 0.97 μM and 4.33 μM, respectively) and inactive towards 17 other kinases (IC50 ≥ 10 μM).
A10162	Brivanib alaninate (BMS-582664)	VEGFR inhibitor	Brivanib alaninate (BMS-582664) is a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling.
A10254 SALE	Brivanib (BMS-540215)	VEGFR-2 inhibitor	Brivanib (BMS-540215) is a VEGFR -2 inhibitor with an IC50 of 25 nM and Ki of 26 nM. Product Citations (1) Hirosumi Tamura,et al. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues, Oncol Rep, 2018, Aug; 40(2): 635-646 29917168
A10703 SALE	PD173074	FGFR1/VEGFR2 Inhibitor	PD173074 is a potent, cell permeable and ATP competitive inhibitor of FGFR and VEGFR. Product Citations (1) Cheryl Q.E. Lee,et al. What Is Trophoblast? A Combination of Criteria Define Human First-Trimester Trophoblast, Stem Cell Reports, 2016, Feb 9; 6(2): 257-272 26862703
A10587	MGCD-265 (Glesatinib)	c-Met inhibitor	MGCD265 is a multitargeted tyrosine kinase inhibitor that binds to and inhibits the phosphorylation of several RTKs, including the c-Met receptor (HGFR); the Tek/Tie-2 receptor; VEGFR types 1, 2, and 3; and MST1R.
A10043 SALE	AEE788	EGFR inhibitor	AEE788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor that inhibits phosphorylation of the tyrosine kinases of EGFR, HER2 and VEGF2.
A10137 SALE	Bibf1120 (Vargatef)	VEGFR inhibitor	BIBF1120 (Vargatef) is a novel triple angiokinase inhibitor that inhibits three growth factor receptors simultaneously: VEGFR, PDGF and FGFR. Product Citations (2) Samuel Q. Li, etc. Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534). PLoS One. 2013; 8(10): e76551. A Sikora ,etc. BIBF 1120 w terapii angiogennej nowotworów. Porównanie szybkości uwalniania pantoprazolu z tabletek dojelitowych i układów wielozbiornikowych, 2014, 70(5), 235-239.

Ordering online

Found your products but not ready to order?

Ordering offline

Signaling Pathways

Proteins

Services

Featured

Order & Inquiry

Technical

Accounts receivable

VEGFR

Ordering online

Found your products but not ready to order?

Ordering offline

Services

Featured

Order & Inquiry

Technical

Accounts receivable

VEGFR

A15073

A15760

A15287

A15271

A15261

A15260

A15250

A15182

A11772

A11496 SALE

A11557

A11558 SALE

A11581 SALE

A13111 SALE

A13234

A12437 SALE

A11396 SALE

A11244 SALE

A12027 SALE

A11955

A11954

A11737 SALE

A11518 SALE

A11263

A13820

A13819

A11472 SALE

A16237

A16197

A12693 SALE

A13240

A14387

A15792

A15272

A15263

A15218

A13555

A13545

A14393

A14156

A13465

A13377

A16342

A10504

A10162

A10254 SALE

A10703 SALE

A10587

A10043 SALE

A10137 SALE

Receive our newsletter